BIIB250502P118000
- 0.13
- 0.000.00%
Biogen Newsroom
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $121 to $255
Biogen Is Maintained at Buy by Canaccord Genuity
Biogen Price Target Cut to $220.00/Share From $265.00 by Canaccord Genuity
Canaccord Genuity Adjusts Price Target on Biogen to $220 From $265
HC Wainwright & Co. Maintains Buy on Biogen, Lowers Price Target to $187
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $144 to $220
Baird Maintains Outperform on Biogen, Lowers Price Target to $255
Biogen Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Achieve Life Sciences (ACHV)
Research Alert: Biib Reports Q1 Results: Top- And Bottom-line Beat, 2025 Guidance Disappoints
Biogen: Balanced Outlook With Hold Rating Amid Mixed Financial Signals
Biogen's Strong Q1 Performance and Strategic Focus Justify Buy Rating
Truist Financial Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $199
Biogen Price Target Cut to $199.00/Share From $210.00 by Truist Securities
Biogen Is Maintained at Buy by Truist Securities
Biogen Analyst Ratings
Piper Sandler Maintains Neutral on Biogen, Lowers Price Target to $115
HSBC Downgrades Biogen to Hold From Buy, Adjusts Price Target to $118 From $342
Biogen Analyst Ratings
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $217